Business Context and Reporting Period
Company: Arrowhead Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2026
Reporting Period: Events occurring on January 7, 2026, with closing dates expected on January 9, 2026 (Equity) and January 12, 2026 (Notes).
Key Financial Metrics and Capital Structure Changes
This filing details two simultaneous capital raising transactions entered into on January 7, 2026:
- Equity Offering:
- Shares Issued: 3,100,776 shares of Common Stock at $64.50 per share.
- Pre-Funded Warrants: Warrants to purchase up to 1,550,387 shares at $64.499 per share.
- Over-Allotment: Underwriters exercised the full option to purchase an additional 456,116 shares on January 8, 2026.
- Net Proceeds: Approximately $216.6 million (after discounts and expenses).
- Convertible Notes Offering:
- Instrument: 0.00% Convertible Senior Notes due 2032.
- Principal Amount: $625,000,000 initial issuance.
- Over-Allotment: Underwriters exercised the full option to purchase an additional $75,000,000 on January 8, 2026.
- Net Proceeds: Approximately $681.3 million (after discounts and expenses).
Total Expected Net Proceeds: Approximately $897.9 million ($216.6 million + $681.3 million).
Material Changes Versus Prior Period
The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as it is a Current Report (8-K) focused on specific corporate events rather than periodic financial performance. The material change is the significant increase in liquidity and the expansion of the company's capital structure through the issuance of new equity and zero-coupon convertible debt.
Guidance, Outlook, and Risks
Management Commentary: The company priced both offerings on January 7, 2026, with closings expected shortly thereafter. The proceeds are intended to fund the company's operations and strategic initiatives, though specific allocation details are not provided in this text.
Risks and Contingencies:
- Closing Conditions: Both offerings are subject to customary closing conditions.
- Ownership Limits: Pre-Funded Warrants include a 9.99% beneficial ownership limitation, which can be increased with 61 days' prior written notice.
- Indemnification: The Company agreed to indemnify underwriters against liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing dates (January 9, 2026 for Equity; January 12, 2026 for Notes) and confirm receipt of proceeds.
- Review the full terms of the 0.00% Convertible Senior Notes due 2032, specifically the conversion rate and any redemption provisions not detailed in this summary.
- Confirm the final number of shares issued after the full exercise of the over-allotment options for both the equity and notes offerings.
- Assess the dilution impact of the 3,100,776 common shares plus the 1,550,387 pre-funded warrants on existing shareholders.
- Examine the "Use of Proceeds" section in the final prospectus supplement (filed January 8, 2026) for specific strategic deployment of the ~$898 million raised.